Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Neurology

• Publication date

  2003-12-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/01.WNL.0000095218.26363.7BPMID 14663016
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Adenosine A2A receptors inhibit the conductance of NMDA receptor channels in rat neostriatal neurons

  2005cited by this paper
• Cellular and behavioural effects of the adenosine A2a receptor antagonist KW‐6002 in a rat model of l‐DOPA‐induced dyskinesia

  2003cited by this paper
• Inactivation of Adenosine A2A Receptors Selectively Attenuates Amphetamine-Induced Behavioral Sensitization

  2003cited by this paper
• Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia

  2003cited by this paper
• Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment.

  2003cited by this paper
• Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors.

  2002cited by this paper
• Effects of adenosine A1 and A2A receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes

  2002cited by this paper
• Persistent Behavioral Sensitization to Chronic l-DOPA Requires A2A Adenosine Receptors

  2002cited by this paper
• DeltaFosB: a sustained molecular switch for addiction.

  2001cited by this paper
• The role and regulation of adenosine in the central nervous system.

  2001cited by this paper
• The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice.

  2001cited by this paper
• The role of the D2 dopamine receptor (D2R) in A2A adenosine receptor (A2AR)-mediated behavioral and cellular responses as revealed by A2A and D2 receptor knockout mice

  2001cited by this paper
• Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice

  2001cited by this paper
• Motor fluctuations and dyskinesia in Parkinson's disease.

  2001cited by this paper
• Absence of the adenosine A(2A) receptor or its chronic blockade decrease ethanol withdrawal-induced seizures in mice.

  2001cited by this paper
• Repeated Cocaine Administration Attenuates Group I Metabotropic Glutamate Receptor-Mediated Glutamate Release and Behavioral Activation: A Potential Role for Homer

  2001cited by this paper
• Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease

  2001cited by this paper
• Functional striatal hypodopaminergic activity in mice lacking adenosine A2A receptors

  2001cited by this paper
• Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease

  2001cited by this paper
• The Selective mGlu5 Receptor Agonist CHPG Inhibits Quinpirole-Induced Turning in 6-Hydroxydopamine-Lesioned Rats and Modulates the Binding Characteristics of Dopamine D2 Receptors in the Rat Striatum Interactions with Adenosine A2a Receptors

  2001cited by this paper
• The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors.

  2001cited by this paper
• ΔFosB: A sustained molecular switch for addiction

  2001cited by this paper
• Inactivation of adenosine A2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission.

  2001cited by this paper
• Striatal molecular mechanisms and motor dysfunction in Parkinson's disease.

  2001cited by this paper
• Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6‐hydroxydopamine‐lesioned rats

  2001cited by this paper
• Selective inhibition by adenosine of mGluR IPSPs in dopamine neurons after cocaine treatment.

  2000cited by this paper
• Levodopa motor complications in Parkinson's disease.

  2000cited by this paper
• Inhibition by adenosine A2A receptors of NMDA but not AMPA currents in rat neostriatal neurons

  2000cited by this paper
• Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors.

  2000cited by this paper
• Roles of adenosine A(1) and A(2A) receptors in the expression and development of methamphetamine-induced sensitization.

  2000cited by this paper
• Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.

  2000cited by this paper
• Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.

  2000cited by this paper
• Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism.

  2000cited by this paper
• Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments

  2000cited by this paper
• Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint

  1999cited by this paper
• Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.

  1999cited by this paper
• Activation of dopamine D2 receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms.

  1999cited by this paper
• Distribution, biochemistry and function of striatal adenosine A2A receptors.

  1999cited by this paper
• Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys

  1999cited by this paper
• Actions of caffeine in the brain with special reference to factors that contribute to its widespread use.

  1999cited by this paper
• Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease.

  1999cited by this paper
• Levodopa therapy

  1998cited by this paper
• Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease.

  1998cited by this paper
• Decreased Presynaptic Sensitivity to Adenosine after Cocaine Withdrawal

  1998cited by this paper
• Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-dopa-induced dyskinesia.

  1998cited by this paper
• L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNA

  1998cited by this paper
• Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

  1998cited by this paper
• The role of nigrostriatal dopamine in metabotropic glutamate agonist-induced rotation.

  1998cited by this paper
• Parkinson's disease. First of two parts.

  1998cited by this paper
• Adenosine A2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys

  1998cited by this paper
• Adenosine A2A receptors modify motor function in MPTP‐treated common marmosets

  1998cited by this paper
• The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants.

  1998cited by this paper
• Parkinson's disease. Second of two parts.

  1998cited by this paper
• Agonists of A1 and A2A adenosine receptors attenuate methamphetamine-induced overflow of dopamine in rat striatum.

  1998cited by this paper
• Diabetic Glomerulopathy in Young IDDM Patients

  1998cited by this paper
• Metabotropic Glutamate Agonist-Induced Rotation: A Pharmacological, FOS Immunohistochemical, and [14C]-2-Deoxyglucose Autoradiographic Study

  1997cited by this paper
• Parkinson's disease: prospects for improved drug therapy.

  1997cited by this paper
• Molecular and cellular basis of addiction.

  1997cited by this paper
• Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease.

  1997cited by this paper
• A Postsynaptic Interaction between Dopamine D1 and NMDA Receptors Promotes Presynaptic Inhibition in the Rat Nucleus Accumbens via Adenosine Release

  1997cited by this paper
• Determination of the effects of caffeine and carbamazepine on striatal dopamine release by in vivo microdialysis.

  1997cited by this paper
• The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons.

  1996cited by this paper
• A common mechanism mediates long-term changes in synaptic transmission after chronic cocaine and morphine.

  1996cited by this paper
• Caffeine-induced expression of c-fos mRNA and NGFI-A mRNA in caudate putamen and in nucleus accumbens are differentially affected by the N-methyl-D-aspartate receptor antagonist MK-801.

  1996cited by this paper
• Effect of long-term haloperidol treatment on striatal neuropeptides: relation to stereotyped behavior.

  1996cited by this paper
• Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behavior and striatal c-Fos induction in 6-hydroxydopamine-lesioned rats.

  1996cited by this paper
• Blockade of A2a Adenosine Receptors Positively Modulates Turning Behaviour and c‐Fos Expression Induced by D1 Agonists in Dopamine‐denervated Rats

  1996cited by this paper
• A2 adenosine receptors: their presence and neuromodulatory role in the central nervous system.

  1996cited by this paper
• Network-level changes in expression of inducible Fos-Jun proteins in the striatum during chronic cocaine treatment and withdrawal.

  1996cited by this paper
• Adenosine A2 receptor-mediated excitatory actions on the nervous system.

  1996cited by this paper
• Pharmacology of adenosine A2A receptors.

  1996cited by this paper
• MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats.

  1996cited by this paper
• Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum.

  1996cited by this paper
• Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum.

  1995cited by this paper
• Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats.

  1995cited by this paper
• Adenosine A2 receptor-mediated modulation of contralateral rotation induced by metabotropic glutamate receptor activation.

  1995cited by this paper
• The selective A2 adenosine receptor agonist CGS 21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex.

  1992cited by this paper
• Adenosine-dopamine interactions in the brain.

  1992cited by this paper
• Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease.

  1991cited by this paper
• Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance.

  1991cited by this paper
• Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats.

  1991cited by this paper
• Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release.

  1990cited by this paper
• Biochemistry of Parkinson's disease 28 years later: A critical review

  1989cited by this paper
• The Role and Regulation of Adenosine in the Central Nervous System

  year unknowncited by this paper

• The role of istradefylline in the Parkinson’s disease armamentarium

  2023cites this paper
• Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson’s disease?

  2020cites this paper
• Adenosine A2A Receptor as a Potential Drug Target - Current Status and Future Perspectives.

  2019cites this paper
• Morphological Plasticity in the Striatum Associated With Dopamine Dysfunction

  2017cites this paper
• The safety of istradefylline for the treatment of Parkinson’s disease

  2015cites this paper
• Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson’s Disease

  2015cites this paper
• The adenosine neuromodulation system in schizophrenia.

  2014cites this paper
• 8-(Furan-2-yl)-3-phenethylthiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidine-2(3H)-thione as novel, selective and potent adenosine A(2A) receptor antagonist.

  2014cites this paper
• Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations

  2013cites this paper
• Design and synthesis of (4E)-4-(4-substitutedbenzylideneamino)-3-substituted-2,3-dihydro-2-thioxothiazole-5-carbonitrile as novel A2A receptor antagonists.

  2013cites this paper
• Conditional neural knockout of the adenosine A(2A) receptor and pharmacological A(2A) antagonism reduce pilocarpine-induced tremulous jaw movements: studies with a mouse model of parkinsonian tremor.

  2013cites this paper
• Neuroimaging over the course of Parkinson's disease: from early detection of the at-risk patient to improving pharmacotherapy of later-stage disease.

  2012cites this paper
• Adenosine A2A receptor antagonism and genetic deletion attenuate the effects of dopamine D2 antagonism on effort-based decision making in mice.

  2012cites this paper
• The molecular basis of dopaminergic brain imaging in Parkinson's disease.

  2012cites this paper
• Award Number: W81XWH-11-1-0150 TITLE: Protection by Purines in Toxin Models of Parkinson's Disease PRINCIPAL INVESTIGATOR:

  2012cites this paper
• Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies.

  2011cites this paper
• Leaf extract of Rhus verniciflua Stokes protects dopaminergic neuronal cells in a rotenone model of Parkinson's disease

  2011cites this paper
• Antioxidant Activity and Protective Effects of Tripterygium regelii Extract on Hydrogen Peroxide-Induced Injury in Human Dopaminergic Cells, SH-SY5Y

  2010cites this paper
• Effects of the detoxified extract of Rhus verniciflua on regulation of catecholamine biosynthesis

  2009cites this paper
• Behavioral genetic contributions to the study of addiction-related amphetamine effects.

  2008cites this paper
• Caffeine Stimulates Cytochrome Oxidase Expression and Activity in the Striatum in a Sexually Dimorphic Manner

  2008cites this paper
• Adenosine A2A receptors, dopamine D2 receptors and their interactions in Parkinson's disease

  2007cites this paper
• Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease.

  2007cites this paper
• Effects of the A 2A adenosine receptor antagonist KW6002 in the nucleus accumbens in vitro and in vivo.

  2006cites this paper
• Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson's disease. Relevance for L-dopa induced dyskinesias.

  2006cites this paper
• ForebrainAdenosineA 2A ReceptorsContributeto L-3,4- Dihydroxyphenylalanine-InducedDyskinesiain HemiparkinsonianMice

  2006cites this paper
• Forebrain Adenosine A2A Receptors Contribute to l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia in Hemiparkinsonian Mice

  2006cites this paper
• A walk through the management of Parkinson s disease.

  2005cites this paper
• Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockade

  2005cites this paper
• Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease.

  2005cites this paper
• Adenosine, glutamate and pH: interactions and implications

  2005cites this paper
• Pathophysiological basis of drug-induced dyskinesias in Parkinson's disease.

  2005cites this paper